Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Prospective, Single-arm, Open-label Trial With a Prespecified Effectiveness Endpoint to Evaluate the Benefits of Haemodynamically Guided Treatment Using the Seerlinq HeartCore System in Heart-failure Patients.

NCT06641921 is registered in ClinicalTrials.gov with Seerlinq s. r. o. as lead sponsor.

NCT NCT06641921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06641921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Prospective, Single-arm, Open-label Trial With a Prespecified Effectiveness Endpoint to Evaluate the Benefits of Haemodynamically Guided Treatment Using the Seerlinq HeartCore System in Heart-failure Patients.
Lead sponsor
Seerlinq s. r. o.
Phase
Not applicable
Overall status
Completed
Start date
May 1, 2024
Completion date
May 1, 2026
Enrollment
330 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, remote monitoring